Use

Anti-Jo-1 antibodies are present in approximately 20% to 30% of patients with adult-onset polymyositis syndromes. They are present in more than 65% of patients who have both myositis and interstitial lung disease. In such patients, the presence of anti-Jo-1 antibodies may be predictive of a response to steroid treatment. Evaluating patients for anti-Jo-1 antibodies is useful for diagnosing polymyositis, dermatomyositis, or polymyositis-scleroderma overlap syndrome.